🇺🇸 Methylene blue infusion in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Akathisia — 1 report (10%)
  2. Aphasia — 1 report (10%)
  3. Blood Phosphorus Increased — 1 report (10%)
  4. Delayed Recovery From Anaesthesia — 1 report (10%)
  5. Drug Toxicity — 1 report (10%)
  6. Dyskinesia — 1 report (10%)
  7. Glasgow Coma Scale Abnormal — 1 report (10%)
  8. Inflammation — 1 report (10%)
  9. Medication Error — 1 report (10%)
  10. Mental Status Changes — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Methylene blue infusion approved in United States?

Methylene blue infusion does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methylene blue infusion in United States?

Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva is the originator. The local marketing authorisation holder may differ — check the official source linked above.